Ms. Tomasello has over three decades of experience in Biotech and Pharma. Her leadership career has positively impacted four blockbuster products in oncology including RITUXAN®, REVLIMID®, POMALYST® and IMBRUVICA®. Previously, Ms. Tomasello was Chief Commercial Officer at Pharmacyclics until its acquisition by AbbVie. From 2005 to 2014, Ms. Tomasello held roles of increasing responsibility at Celgene Corporation, including President of the Americas, Hematology and Oncology, where she managed more than $4 billion in revenue. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of the commercial organization encompassing multiple brands spanning 11 indications. In addition, she was instrumental in strategic decision-making regarding global expansion and M&A evaluations, which led to the acquisition and integration of Pharmion Corporation, Gloucester Pharmaceuticals, Inc. and Abraxis Biosciences, Inc. Prior to joining Celgene, Ms. Tomasello was the National Director of Hematology for RITUXAN® at Genentech, where she was responsible for more than $1.7 billion in revenue and all in-line and new indications for the hematology commercial sales organization. Earlier in her career, she held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. Ms. Tomasello currently serves on the board of directors for Oxford BioTherapeutics and Diplomat. While at Celgene, she served as a board member of BIONJ and has been a member of the advisory board for Healthcare Businesswomen’s Association (HBA). Ms. Tomasello received her B.S. in marketing from the University of Cincinnati and her M.B.A. from Murray State University, KY.